Biogazelle Presents the Ultimate qPCR-Based lncRNA Profiling Platform - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Biogazelle Presents the Ultimate qPCR-Based lncRNA Profiling Platform

lncRNAs represent an emerging important class of regulatory transcribed elements. The study of lncRNAs is timely and relevant, because of their implication in important cellular processes, through new modes of action. The lncRNA genes are generally low abundant, which is exactly why there is a genuine need for a platform with ultimate sensitivity superseding microarray-based platforms. Biogazelle’s qPCR service solution is the first to accommodate this need.

Biogazelle has developed a revolutionary platform for accurate and sensitive expression profiling of 1718 human long non-coding RNAs (lncRNAs). The platform consists of state-of-the-art validated qPCR assays for 1666 long intergenic ncRNAs (lincRNAs) and 52 lncRNAs.

Experiments are set-up in 5184-well SmartChips (Wafergen). A low-volume liquid handler enables fast and high-precision pipetting and low volume qPCR reactions to ensure fast turn-around times at affordable costs. The 1718 SYBR Green I RT-qPCR assays are strictly validated according to the MIQE guidelines, and meet Biogazelle’s strict quality control criteria in terms of optimal PCR efficiency, specificity, sensitivity and linear dynamic range of quantification.

Data analysis is performed using our qbasePLUS software, which is built upon a state-of-the-art quantification model. Thorough post-PCR quality control ensures reliable results. The calculation parameters and quality control settings are tailored toward the need of the lincRNA project. Both raw data and processed results (e.g. global mean normalised relative quantities) are delivered in an easy to understand format.

More About This Company